Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.54 |
| ▸ | GABRD | O14764 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.54 |
| ▸ | GABRE | P78334 | 2/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | GRM8 | O00222 | 1/20 | 0.54 |
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7780572 | 1.00 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2241803 | 0.84 | LMNA (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5964545 | 0.84 | ALOX15 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4537585 | 0.84 | LMNA (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28096046 | 0.84 | LMNA (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7775146 | 0.84 | ALOX15 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23408823 | 0.83 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4379768 | 0.83 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1767320 | 0.82 | CYP1A2 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10874134 | 0.82 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117017830-A | Solubilizing composition and use thereof | 华熙生物科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-8084499-B2 | Modified clay mineral | AJINOMOTO CO., INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090098169-A1 | MODIFIED CLAY MINERAL | AJINOMOTO CO., INC (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0572167-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098169-A1 | MODIFIED CLAY MINERAL | CUTA, ARG1, AS3MT | GABRP 4328/4885GABRD 4736/4885GABRA1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.